Details for Patent: 12,714,697
Which drugs does patent 12,714,697 protect, and when does it expire?
Patent 12,714,697 protects FILSPARI and is included in one NDA.
This patent has twenty-six patent family members in eleven countries.
Drugs Protected by US Patent 12,714,697
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Travere | FILSPARI | sparsentan | TABLET;ORAL | 216403-001 | Feb 17, 2023 | RX | Yes | No | 12,714,697 | ⤷ Start Trial | TREATMENT OF PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) IN ADULTS AT RISK FOR DISEASE PROGRESSION | ⤷ Start Trial | ||||
| Travere | FILSPARI | sparsentan | TABLET;ORAL | 216403-002 | Feb 17, 2023 | RX | Yes | Yes | 12,714,697 | ⤷ Start Trial | TREATMENT OF PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) IN ADULTS AT RISK FOR DISEASE PROGRESSION | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,714,697
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2017341825 | ⤷ Start Trial | |||
| Australia | 2023219839 | ⤷ Start Trial | |||
| Australia | 2025271121 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
